UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934

Date of Report (date of earliest event reported): ~~March~~April 3014, 2011

JIANGBO PHARMACEUTICALS, INC.

(Exact name of registrant as specified in charter)

Florida

(State or other jurisdiction of incorporation)

001-34763	~~001~~65-~~34763~~1130026	~~65-1130026~~
(Commission File Number)	(~~Commission~~IRS ~~File~~Employer ~~Number~~Identification No.)	~~(IRS Employer Identification No.)~~
25 Haihe Road, Laiyang Economic Development
Laiyang City, Yantai, Shandong Province, People’s Republic of China 265200
(Address of principal executive offices and zip code)
	(0086) 535-7282997
	(Registrant's telephone number including area code)
	(Registrant's former name or former address, if changed since last report)

25 Haihe Road, Laiyang Economic Development

Laiyang City, Yantai, Shandong Province, People’s Republic of China 265200

(Address of principal executive offices and zip code)

(0086) 535-7282997

(Registrant's telephone number including area code)

(Registrant's former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 4.01 Changes in Registrant’s Certifying Accountant.

~~On March 30, 2011,~~ Jiangbo Pharmaceuticals, Inc. (the “Company”) ~~engaged~~was notified that, effective April 14 2011, the practice of Bernstein & Pinchuk LLP (“B&P”), asthe ~~its~~Company’s ~~principal~~independent ~~accountant~~registered topublic ~~replace~~accounting ~~Frazer Frost~~firm, ~~LLP~~entered ~~(“FF”),~~into ~~who~~a ~~advised~~joint ~~the~~venture ~~Company~~agreement ~~that~~with itMarcum ~~did~~LLP ~~not~~and ~~intend~~formed toMarcum ~~stand~~Bernstein ~~for~~& ~~re-appointment~~Pinchuk asLLP ~~the~~(“Marcum ~~Company’s~~BP”) ~~principal~~in ~~accountant~~a ~~for~~transaction pursuant to which B&P merged its ~~next~~China ~~fiscal~~operations ~~year.~~into ~~The~~Marcum ~~Company~~BP and ~~decided~~certain toof ~~engaged~~the professional staff of B&P atjoined ~~this~~Marcum ~~time~~BP inas ~~order~~employees toof ~~ensure~~Marcum anBP. ~~orderly~~Accordingly, ~~transition~~effective ~~from~~April FF14, to2011, B&P~~. The~~ ~~change~~resigned inas ~~accountants was approved by~~ the Company's ~~Board~~independent ofregistered ~~Directors~~public accounting firm and Marcum BP became the ~~Audit~~Company's ~~Committee~~independent ~~and~~registered ~~did~~public ~~not~~accounting ~~result~~firm. ~~from~~Marcum ~~any~~BP ~~dissatisfaction~~is currently registered with the ~~quality~~Public ofCompany ~~professional~~Accounting ~~services~~and ~~rendered~~Oversight byBoard FF(PCAOB).

InThis ~~connection~~change ~~with~~in the ~~audit of the~~ Company's ~~financial~~independent ~~statements~~registered ~~for~~public ~~the~~accounting ~~fiscal~~firm ~~years~~was ~~ended~~approved ~~June~~by ~~30,~~the ~~2010~~Audit ~~and~~Committee ~~2009~~of ~~and~~ the ~~subsequent~~Company's ~~interim~~Board ~~period,~~of ~~(i)~~Directors ~~there were no disagreements with FF~~ on ~~any~~April ~~matter of accounting principles or practices~~19, ~~financial~~2011. ~~statement~~Marcum ~~disclosure,~~BP orwas ~~auditing~~engaged ~~scope~~as orthe ~~procedures, which disagreements, if not resolved to FF~~Company's ~~satisfaction,~~independent ~~would~~registered ~~have~~public ~~caused~~accounting FFfirm toon ~~make~~April ~~reference in connection with its opinion to the subject matter of the disagreement~~19, ~~and (ii) there were no “reportable events,” as that term is described in Item 304(a)(1)(v) of Regulation S-K~~2011.

~~Attached~~During asthe ~~Exhibit~~Company’s ~~16.1~~most istwo recent fiscal years ended June 30, 2010 and 2009 and through April 20, 2011, the Company did not consult with Marcum BP on (i) the application of accounting principles to a ~~copy~~specified transaction, either completed or proposed, or the type of ~~FF's~~audit ~~letter~~opinion ~~addressed~~that tomay be rendered on the ~~SEC~~Company’s ~~relating~~financial statements, and Marcum BP did not provide either a written report or oral advice to the ~~statements~~Company ~~made~~that was an important factor considered by the Company in ~~this~~reaching ~~Current~~a ~~Report~~decision onas ~~Form~~to 8any accounting, auditing, or financial reporting issue; or (ii) the subject of any disagreement, as defined in Item 304 (a)(1)(iv) of Regulation S-K and the related instructions, or a reportable event within the meaning set forth in Item 304(a)(1)(v) of Regulation S-K.

~~During~~B&P was engaged by the Company's ~~two~~on ~~most~~March ~~recent~~30, ~~fiscal~~2011 ~~years~~ and inas ~~the~~a ~~subsequent~~result ~~interim~~did ~~period~~not ~~prior~~prepare tothe ~~March~~audits ~~30,~~of ~~2011,~~ the Company’s ~~did~~financial ~~not~~statements ~~consult~~for ~~with~~the ~~B&P~~fiscal ~~regarding~~years ~~(i)~~ended June 30, 2010 and 2009 and through the ~~application~~date of ~~accounting~~this ~~principles~~Current toReport. As a ~~specific~~result, ~~completed~~in orconnection ~~contemplated~~with ~~transaction,~~the oraudits of the ~~type~~Company’s offinancial ~~audit~~statements ~~opinion~~for ~~that~~the ~~might~~fiscal beyears ~~rendered~~ended onJune 30, 2010 and 2009 and through the ~~Company's~~date ~~consolidated~~of ~~financial~~this ~~statements~~Current ~~and~~Report, nothere ~~written~~were: or(i) no ~~oral~~disagreements ~~advice~~between ~~was~~the ~~provided~~Company byand B&P ~~that~~on ~~was~~any anmatters ~~important~~of ~~factor~~accounting ~~considered~~principles byor ~~the~~practices, ~~Company~~financial instatement ~~reaching~~disclosure, aor ~~decision~~auditing asscope toor ~~the~~procedures, ~~accounting~~which disagreements, ~~auditing~~if ornot ~~financial~~resolved ~~reporting~~to ~~issue~~the orsatisfaction ~~(ii)~~of ~~any~~B&P, ~~matter~~would ~~that~~have ~~was~~caused ~~either~~B&P to make reference to the subject matter of athe disagreement orin ~~event,~~their asreports ~~set~~on ~~forth~~the inCompany’s ~~Item~~financial ~~304~~statements for such years, and (aii)~~(1)(iv)~~ orno ~~Item~~reportable events within the meaning set forth in Item 304(a)(1)(v) of Regulation S-K.

The Company has provided B&P a copy of the disclosures in this Form 8-K and has requested that B&P furnish it with a letter addressed to the Securities and Exchange Commission stating whether or not B&P agrees with the Company’s statements in this Item 4.01(a). A copy of the letter dated April 20, 2011, furnished by B&P in response to that request is filed as Exhibit 16.1 to this Form 8-K.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.	Description	~~Description~~
16.1	Letter of Bernstein & Pinchuk LLP to the SEC, dated April 20, 2011.	~~Letter of Frazer Frost, LLP to the SEC, dated as of April 1, 2011.~~

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	JIANGBO PHARMACEUTICALS, INC.

	By:	/s/ Jin Linxian
	Name: Jin Linxian
	Title: Chief Executive Officer

Dated: April 420, 2011

Filing Compare · Jiangbo Pharmaceuticals, Inc.